AICA-ribosiduria Due to ATIC Deficiency

1

Review clinical trials related to AICA-ribosiduria Due to ATIC Deficiency. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Purine Supplementation in Patients With AICA-Ribosiduria

AICA-Ribosiduria due to ATIC deficiency is a rare genetic metabolic disease that affects less than 10 patients (PMID: 32557644). It results in severe polyhandicap linked to neurodevelopmental disorders, visual impairment, growth retardation, severe spinal deformities and scoliosis, and often early-onset epilepsy. The disease is caused by dysfunction of the ATIC enzyme, which is involved in de novo purine biosynthesis. A recent study (PMID: 38244287) reported a decrease in disease biomarkers in a single patient after 3 months on a purine-rich diet, which persisted for at least 1 year. The investigators propose to replicate this study on several patients to investigate the potential of this treatment for this severe orphan disease.

Participants needed: 10
Trial details
Age: 3+Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Universitaire de Saint EtienneUpdated: May 8, 2026Locations: 1
Eligibility criteria

Individual affected by AICA-ribosiduria due to ATIC deficiency